A Phase 4 interventional study of Sertraline in Major Depressive Disorder and Chronic Major Depression, Recurrent, sponsored by University of Texas at Austin. Recruiting at 1 site in United States. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-05-01.
Sponsored by University of Texas at Austin · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 44 studies testing sertraline in Depressive Disorder, Major — 6 open to participants now, 7 under way, none of them phase 3. Sertraline · Depressive Disorder, Major.
Among the 44 studies testing sertraline in Depressive Disorder, Major, this one is the 27th largest by planned enrollment, is the only one that started in 2023, is one of 16 in phase 4, and was the 38th registered.
3,051 studies on the registry are indexed under Depressive Disorder, Major; 596 are open to participants now.
Browse Depressive Disorder, Major studies →6 of the 44 studies testing sertraline in Depressive Disorder, Major are open now, in 4 countries. Recruiting first, the newest first:
First Affiliated Hospital of Chongqing Medical University · Sites in China
Ages 12–18
First Affiliated Hospital of Chongqing Medical University · Sites in China
Ages 12–18
University of Bern · Sites in Zimbabwe
Ages 18+
Poznan University of Medical Sciences · Sites in Poland
Ages 12+
Xinyu Zhou · Sites in China
Ages 12–17
By country, each count listing its studies:
Sertraline: first FDA approval 1991 (ZOLOFT). What it is approved for, and how studies give it, is on its page →
Of the 419 Depressive Disorder, Major studies recruiting now, 93 (22%) set no upper age limit and 299 (71%) stop at 75 or younger; 55 take children under 18; 100 take healthy volunteers.
This study: 18 Years to 65 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
44 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 9 · Phase 3 7 · Phase 4 16
First in 1998; this study’s year is marked. 1 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 50 is below the median of 80 across 2,535 interventional studies indexed under Depressive Disorder, Major.
Median enrollment 78 across the 44 interventional studies. Of the 31 that completed or were terminated, 12 (39%) have results posted.
This tab as a report to print or save as PDF → With an account.
9 of 44 have an industry lead sponsor. The 10 most frequent:
University of Texas at Austin is the lead sponsor of 328 studies on the registry; 79 are open to participants now.
Of its 10 completed or terminated interventional studies of FDA-regulated products, 5 (50%) have results posted.
University of Texas at Austin has 9 studies filed under Depressive Disorder, Major — fewer than ten, so there is no comparison to draw.
4 of the studies testing sertraline in Depressive Disorder, Major that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05273996David SteffensPredictors of Cognitive Outcomes in Geriatric Depression | 2027-04-30 |
| NCT07011693Xinyu ZhouSwitching Medication and Augmentation Strategies for SSRI-Resistant Adolescent Depression(SMART-I) | 2027-06 |
| NCT05892744University of Texas at AustinEstablishing Multimodal Brain Biomarkers for Treatment Selection in Depression | 2027-07-15 |
| NCT07478796Poznan University of Medical SciencesTDM-Guided Treatment With SSRIs in Hospitalized Adults and Children | 2027-11-30 |
Add all 4 to your calendar (.ics) → With an account.
Among the 44 studies testing sertraline in Depressive Disorder, Major, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of the study is to identify brain biomarkers and characteristics that predict individual responses to treatment of major depression with the antidepressant drug sertraline (tradename Zoloft), a common selective serotonin reuptake inhibitor (SSRI) antidepressant. Our central hypothesis is that brain activity and connections jointly measured with functional magnetic resonance imaging (fMRI) and electroencephalogram (EEG) will be able to predict an individual's response to sertraline treatment.
Our prior published studies found that sertraline outcome was predicted by biomarkers, primarily in frontoparietal control (FPCN), default mode (DMN), and ventral attention networks (VAN), from different single-modality neuroimaging data, including fMRI activation during emotional conflict regulation, resting EEG power signature, and resting fMRI connectivity. Our recent study with resting EEG connectivity defined two sertraline-predictive subtypes that showed convergent validity between EEG and fMRI. Therefore, the investigators hypothesize that modality-specific regional activity/connections in these networks exhibit similar subject-wise covariation that will jointly predict sertraline treatment response more precisely than either modality alone. However, the derivation of multimodal biomarkers remains highly challenging and underexplored for treatment selection in depression. The overall objective of this proposal is to establish multimodal brain biomarkers using data-driven analytics for treatment selection in depression. With multimodal data from EMBARC, a large publicly-available dataset, the investigators will devise advanced machine learning models to probe brain biomarkers jointly from multiple feature modalities including resting connectivity, task fMRI activation, and EEG band power. An independent cohort will be collected at Dell Medical School, The University of Texas at Austin (UT Austin) with methodology matching that utilized in the EMBARC study to produce a new sample of participants with independent data to validate these biomarker findings. To this end, the investigators will utilize an integrative analysis of both fMRI and EEG to: 1) identify moderators of sertraline versus placebo response in MDD; 2) quantify brain signatures that predict antidepressant treatment outcome; 3) recruit 50 depressed patients, non-invasively assess brain function with a combination of task and resting state fMRI and EEG prior to treatment initiation, administer/prescribe the common antidepressant medication, sertraline (tradename Zoloft), track symptom response over time, and utilize these data as an independent new cohort to optimize and validate brain biomarkers.
Aim 1: Identify multimodal brain moderators of antidepressant treatment effects of sertraline medication in major depressive disorder (MDD) using an existing, publicly-available database (EMBARC). Task 1.1: Using the EMBARC dataset, the investigators will design a canonical correlation analysis-based method to integrate fMRI and EEG to extract region-wise combined brain features. Task 1.2: The investigators will use linear mixed-effect models in a full intent-to-treat framework with the combined features to identify moderators of sertraline versus placebo. Task 1.3: The investigators will compare the statistical strength of the moderators identified between using multimodal features and each single-modality features, reveal neurobiological mechanisms underlying the multimodal moderators, and interpret their associations with depression-relevant clinical symptoms. This aim is crucial to establish novel multimodal brain moderators that can guide treatment selection in depression from a group-level perspective.
Aim 2: Quantify multimodal brain signatures that predict individual antidepressant treatment response to sertraline treatment in MDD using an existing, publicly-available database. Task 2.1: The Investigators will characterize multimodal brain signatures predictive of individual treatment outcomes using a machine learning tool that incorporates predictive modeling into our well-established latent space model with subtype guidance defined in our prior study. Task 2.2: The Investigators will compare multimodal signatures with single-modality and non-biological factors to confirm their efficacy in treatment outcome prediction and demonstrate their transferability to using EEG alone in clinical practice. Task 2.3: The investigators will investigate which brain regions/connections of different modalities are most critical to delineating the multimodal signatures by examining their associations with single-modality features, and interpret the neurocircuitry models in depression underlying the treatment response. These tasks are necessary for developing multimodal signatures of individual responses to antidepressant treatment for personalized medicine.
Aim 3: Optimize and validate multimodal brain biomarkers using new data collected in an independent, open-label clinical trial of sertraline treatment for MDD. Task 3.1: The investigators will recruit 50 individuals with MDD as an independent cohort and will adopt the EMBARC protocol design, including fMRI and EEG assessments at baseline followed by sertraline prescribed to these patients with clinical assessment of outcomes over 8 weeks. Task 3.2: The investigators will refine the multimodal brain signatures using an adaptive optimization strategy with the samples collected each year. Task 3.3: The investigators will perform an extensive validation using the new cohort to verify the multimodal biomarkers discovered in Aims 1-2. This aim will optimize our biomarker findings and provide strong evidence for their generalizability and reproducibility.
This project will establish informative multimodal biomarkers that can moderate clinical effects and predict individual responses to sertraline treatment, thereby providing a promising new avenue towards one of the first implementations in psychiatry of an objective test to inform treatment selection decisions. Our central hypothesis is that modality-specific regional brain activity/connections in FPCN, DMN, and VAN exhibit similar subject-wise covariation that can jointly predict sertraline treatment response more precisely than either modality alone.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
DSM diagnostic criteria
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Established FDA-approved treatment for major depressive disorder
Drug: Sertraline
50-200mg/day
Also known as: Zoloft
Change from Baseline on the GRID Hamilton Depression Rating Scale (GRID-HAM-D) at 8 weeks
Standardized clinician-administered measure of depression symptom severity. Scores range from 0-52. Lower scores indicate less depressive symptomatology, and so are the more desirable.
Time frame: 8 weeks
Change from Baseline on the Quick Inventory of Depressive Symptomology-Self Report (QIDS-SR) at 8 weeks
Self-report measure of depressive symptom severity. Scores range from 0 to 27.
Time frame: 8 weeks
Change from Baseline on the Columbia-Suicide Severity Rating Scale (C-SSRS) at 8 weeks
Clinician-administered measure of suicidal ideation. Scores range from 0 to 25.
Time frame: 8 weeks
Change from Baseline on the Beck Anxiety Inventory (BAI) at 8 weeks
Self-report measure of anxiety symptom severity. Scores range from 0 to 63.
Time frame: 8 weeks
Change from Baseline on the Spielberger State Trait Anxiety Inventory-Trait Form (STAI-T) at 8 weeks
Self-report measure of trait anxiety. Scores range from 20 to 80.
Time frame: 8 weeks
Change from baseline on the Anger Attacks Questionnaire (AAQ) at 8 weeks
Self-report measure of anger outbursts. Scores range from 5-25.
Time frame: 8 weeks
Change from baseline on the Irritability domain of the Concise Associated Symptom Tracking Scale-Self Report at 8 weeks
Self-report measure of irritability. Scores range from 17 to 85.
Time frame: 8 weeks
Change from baseline on the Snaith-Hamilton Pleasure Scale (SHAPS) at 8 weeks
Self-report measure of anhedonia. Scores range from 0 to 14.
Time frame: 8 weeks
Change from baseline on the Patient Health Questionnaire for depression (PHQ-9) at 8 weeks
Self-report measure of depressive symptom severity. Scores range from 0 to 27.
Time frame: 8 weeks
Change from baseline on the General Anxiety Disorder (GAD-7) at 8 weeks
Self-report measure of generalized anxiety disorder symptoms. Scores range from 0 to 21.
Time frame: 8 weeks
Change from baseline on the Mood and Anxiety Symptom Questionnaire-30 at 8 weeks (MASQ-30)
Self-report measure of general distress related to anxiety and depression. Scores range from 10 to 50.
Time frame: 8 weeks
Change from baseline on the Standardized Assessment of Personality-Abbreviated Scale (SAPAS) at 8 weeks
Assessment of personality. Scores range from 0 to 8.
Time frame: 8 weeks
Change from baseline on the Clinical Global Impressions Scale (CGI) at 8 weeks
Clinician-rated measure of global symptom severity. Scores range from 1 to 7.
Time frame: 8 weeks
Started Sep 2023 (actual). Primary completion is estimated for Jul 2027, 45 months after the start.
Of 79 non-industry phase 4 interventional studies under Depressive Disorder, Major, half reached primary completion within 44 months of starting (the median), counting those still running; a quarter within 25 and three quarters within 60. This study's planned 45 months is close to that.
Counting every sponsor, half of 98 studies reached it within 35 months; a quarter within 20 and three quarters within 58.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Sertraline
University of Texas at Austin →